Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers Identify Less Expensive HIV Progression Test as Effective as Current Tests in Use

17.10.2002


Heat-denatured p24 Antigen Tests Can Cut Cost of HIV Progression Monitoring



Researchers at the Johns Hopkins Bloomberg School of Public Health and the University of Zurich, Switzerland, have identified a test for monitoring the progression of HIV in the early stages of the disease that is less expensive than current tests used to monitor the progression of HIV. The test, called HIV-1 protein 24 (p24) antigen, predicts disease progression as well as CD4 lymphocyte count and HIV-1 RNA viral load, the measurements currently used to determine when patients should start antiviral drug therapy to prevent AIDS. The study, “Heat-Denatured Human Immunodeficiency Virus Type 1 Protein 24 Antigen: Prognostic Value in Adults with Early-Stage Disease,” appears in the Oct. 15 issue of The Journal of Infectious Diseases.

Timothy R. Sterling, MD, a study co-author and assistant professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health said, “The test could be used to determine when to initiate anti-retroviral therapy in HIV-infected persons. And because it costs much less than both CD4 lymphocyte count and HIV-1 RNA viral load, the heat-denatured p24 antigen test could be of particular benefit in developing countries, where the burden of HIV infection is great.”


According to Dr. Sterling, CD4 lymphocytes and HIV-1 RNA are excellent predictors of disease progression as well as a patient’s response to therapy and are used to determine when to initiate anti-retroviral therapy. However, the current tests to monitor CD4 lymphocytes and HIV-1 RNA are expensive. The heat-denatured assay separates antigen-antibody complexes and increases the detection of p24 antigen in patients during the early stages of the disease.

“P24 antigen is a protein in HIV. The test is administered by drawing blood from a patient, heating the plasma, and then measuring the amount of p24 antigen found in the sample. Higher levels of p24 indicates a greater risk of disease progression,” explained Dr. Sterling. The authors found that a p24 level of 5 pg/ml was comparable to a CD4 lymphocyte count of 350 cells/mm3 or a viral load of 30,000 copies/ml (b-DNA).

The 494 participants in the study were injection drug users enrolled in a longitudinal cohort study. Blood samples were obtained and analyzed to quantify T-cell subsets; then HIV-1 RNA and p24 antigen were quantified in specimens that had been frozen after collection. Semiannual follow-up interviews were also held with participants during the five-year study.

Using Johns Hopkins Hospital prices, researchers found that conducting a CD4 lymphocyte count is $88, whereas a HIV-1 RNA level costs $152. The total cost of a p24 antigen test is approximately $20 when used qualitatively and $30 when used quantitatively. Because of the frequency with which monitoring must be performed to assess disease progression and response to therapy, researchers said they believe the heat-denatured p24 antigen test would be much more affordable than the currently available tests. In addition, they said the p24 antigen assay is readily automated and easy to perform, and that storage is less demanding than that required for other tests.

Sterling said, “The heat-denatured p24 antigen test was comparable with that of the HIV-1 RNA and CD4 lymphocytes. In addition to its low cost, it could be used either alone, or in conjunction with the other tests. It would be very useful in making decisions regarding the initiation of anti-retroviral therapy, particularly in resource-poor settings.”

Co-Authors of the study were Donald R. Hoover, Jacquie Astemborski, David Vlahov, John G. Bartlett, and Jorg Schupbach.

The study was funded by the Swiss Federal Office of Public Health, Swiss Human Immunodeficiency Virus Cohort Study/Swiss National Science Foundation, National Institute on Drug Abuse, and National Institute of Allergy and Infectious Diseases.

Public Affairs Media Contacts for the Johns Hopkins Bloomberg School of Public Health: Tim Parsons or Kenna Brigham @ 410-955-6878 or paffairs@jhsph.edu.

Kenna L. Brigham | EurekAlert!
Further information:
http://www.journals.uchicago.edu/JID/home.html
http://www.jhsph.edu/Dept/EPI/index.html

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>